SCHEMBL2543365

SCHEMBL2543365

COCc1cc(Cl)nc(-c2ccc(F)cc2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.47
TDP1 Q9NUW8 2/20 0.47
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
MAPT P10636 4/20 0.43
GAA P10253 1/20 0.43
ALDH1A1 P00352 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
BLM P54132 1/20 0.43
PTGS2 P35354 1/20 0.43
NPC1 O15118 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
POLB P06746 2/20 0.41
CTDSP1 Q9GZU7 1/20 0.41
RECQL P46063 1/20 0.40
MCOLN3 Q8TDD5 1/20 0.40
DHPS P49366 1/20 0.39
GCGR P47871 1/20 0.37
RAB9A P51151 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15210421 0.88 LMNA (0.59) LMNATDP1MEN1KMT2AMAPT
SCHEMBL2541010 0.86 LMNA (0.48) LMNATDP1MEN1KMT2AMAPT
SCHEMBL2539831 0.84 LMNA (0.63) LMNATDP1MEN1KMT2AMAPT
SCHEMBL2538974 0.82 LMNA (0.44) LMNATDP1MEN1KMT2AMAPT
SCHEMBL2537961 0.80 POLB (0.44) LMNAMEN1KMT2AMAPTL3MBTL1
SCHEMBL3450860 0.78 LMNA (0.47) LMNAMEN1KMT2AMAPTL3MBTL1
SCHEMBL5483462 0.77 LMNA (0.48) LMNATDP1MEN1KMT2AMAPT
SCHEMBL9013500 0.74 LMNA (0.68) LMNAMEN1KMT2AMAPTGAA
SCHEMBL15210654 0.73 LMNA (0.60) LMNATDP1MEN1KMT2AMAPT
SCHEMBL19462437 0.71 ALDH1A1 (0.39) LMNATDP1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044055-B2 2-phenyl-6-aminocarbonyl-pyrimidine derivatives and their use as P2Y12 receptor ACTELION PHARMACEUTICALS LTD. (CH) 2011-10-25 US disclosed
US-20090291962-A1 2-PHENYL-6-AMINOCARBONYL-PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ACTELION PHARMACEUTICALS LTD. (CH) 2009-11-26 US disclosed
EP-2079711-A2 2-PHENYL-6-AMINOCARBONYL-PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2009-07-22 EP disclosed
WO-2008050301-A2 2- PHENYL- 6-AMINOCARBONYL- PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291962-A1 2-PHENYL-6-AMINOCARBONYL-PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR P2RY12, P2RY13, P2RY2 LMNA 2912/4885TDP1 1962/4885MEN1 3812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.